Skip to main content
Top
Published in: Medical Oncology 3/2010

01-09-2010 | Original Paper

Biological characteristics of a specific brain metastatic cell line derived from human lung adenocarcinoma

Authors: Ling Hu, Junqing Zhang, Hongbin Zhu, Jie Min, Yingming Feng, Helong Zhang

Published in: Medical Oncology | Issue 3/2010

Login to get access

Abstract

To study the expression of VEGF, MMP-9, EGFR, and S100B in a highly brain metastases sub-clone cell line, PC14/B. The in vitro metastases-related behaviors of PC14 /B cells, such as adhesion to extracellular matrix (ECM), migration, and invasion were determined and compared with primary PC14 cells and A549 cells that do not metastasize to brain. The expression of vascular epithelial growth factor (VEGF), matrix metalloproteinase 9 (MMP-9), S100B, and epidermal growth factor receptor (EGFR) in the above three cell lines were measured by immunohistochemical staining and Western blot assay.The PC14/B cells have enhanced abilities of adhesion, migration, and invasion than PC14 cells and A549 cells. The expression levels of VEGF and MMP-9 in PC14/B cells are much higher than in PC14 and A549 cells. Two protein polymers of S100B are expressed specially in PC14/B cells. The expression of EGFR has a significant lower level in PC14 cells than in the other two cell lines. The increased expression of VEGF and MMP-9 may lead to the enhancement of adhesion, migration, and invasion of PC14/B cells. The expression of EGFR in PC14/B cells may have negative correlation with their capacities of metastasizing to brain. The specific expression of S100B in PC14/B cells strongly suggest that S100B might be a potential target for developing new therapy to brain metastases of lung cancer.
Literature
1.
go back to reference Ishikawa H, Satoh H, Kurishima K, et al. Lung cancer with synchronous brain and bone metastasis. Clin Oncol (R Coll Radiol). 2000;12:136–7. Ishikawa H, Satoh H, Kurishima K, et al. Lung cancer with synchronous brain and bone metastasis. Clin Oncol (R Coll Radiol). 2000;12:136–7.
2.
go back to reference Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.PubMed Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.PubMed
3.
go back to reference Kim LS, Huang S, Lu W, et al. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis. 2004;21:107–18.CrossRefPubMed Kim LS, Huang S, Lu W, et al. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis. 2004;21:107–18.CrossRefPubMed
4.
go back to reference Sierra A, Price JE, Garcia-Ramirez M, et al. Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab Invest. 1997;77:357–68.PubMed Sierra A, Price JE, Garcia-Ramirez M, et al. Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab Invest. 1997;77:357–68.PubMed
5.
go back to reference Lee TH, Avraham HK, Jiang S, et al. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem. 2003;278:5277–84.CrossRefPubMed Lee TH, Avraham HK, Jiang S, et al. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem. 2003;278:5277–84.CrossRefPubMed
6.
go back to reference Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 2000;60:4959–67.PubMed Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 2000;60:4959–67.PubMed
7.
go back to reference Chantrain CF, Shimada H, Jodele S, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004;64:1675–86.CrossRefPubMed Chantrain CF, Shimada H, Jodele S, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004;64:1675–86.CrossRefPubMed
8.
go back to reference Coussens LM, Tinkle CL, Hanahan D, et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–90.CrossRefPubMed Coussens LM, Tinkle CL, Hanahan D, et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–90.CrossRefPubMed
9.
go back to reference Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525–31.CrossRefPubMed Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525–31.CrossRefPubMed
10.
go back to reference Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis. 2005;22:237–46.CrossRefPubMed Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis. 2005;22:237–46.CrossRefPubMed
11.
go back to reference Zhang S, Yang X, Zhao A. Clinical analysis of combination therapy for 252 patients of lung cancer with brain metastasis. Zhonghua Jie He He Hu Xi Za Zhi. 1999;22:475–7.PubMed Zhang S, Yang X, Zhao A. Clinical analysis of combination therapy for 252 patients of lung cancer with brain metastasis. Zhonghua Jie He He Hu Xi Za Zhi. 1999;22:475–7.PubMed
12.
go back to reference RR R, DM B, DJ W. Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat Struct Biol. 2000;7:525–7.CrossRef RR R, DM B, DJ W. Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat Struct Biol. 2000;7:525–7.CrossRef
13.
go back to reference Lin J, Yang Q, Yan Z, et al. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004;279:34071–7.CrossRefPubMed Lin J, Yang Q, Yan Z, et al. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004;279:34071–7.CrossRefPubMed
14.
go back to reference Arcuri C, Bianchi R, Brozzi F, et al. S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation. J Biol Chem. 2005;280:4402–14.CrossRefPubMed Arcuri C, Bianchi R, Brozzi F, et al. S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation. J Biol Chem. 2005;280:4402–14.CrossRefPubMed
15.
go back to reference Millward TA, Heizmann CW, Schafer BW, et al. Calcium regulation of Ndr protein kinase mediated by S100 calcium-binding proteins. EMBO J. 1998;17:5913–22.CrossRefPubMed Millward TA, Heizmann CW, Schafer BW, et al. Calcium regulation of Ndr protein kinase mediated by S100 calcium-binding proteins. EMBO J. 1998;17:5913–22.CrossRefPubMed
16.
go back to reference Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–15.CrossRefPubMed Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–15.CrossRefPubMed
17.
go back to reference Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–67.CrossRefPubMed Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–67.CrossRefPubMed
18.
go back to reference Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37.CrossRefPubMed Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37.CrossRefPubMed
19.
go back to reference Zhang J-q, Zhang H-l, Feng Y-m. Establishment of highly brain metastatic lung cancer cell sub-clone and brain metastatic animal model. J Mod Oncol. 2007;15:48–9. Zhang J-q, Zhang H-l, Feng Y-m. Establishment of highly brain metastatic lung cancer cell sub-clone and brain metastatic animal model. J Mod Oncol. 2007;15:48–9.
20.
go back to reference Hirashima Y, Kobayashi H, Suzuki M, et al. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells. J Biol Chem. 2003;278:26793–802.CrossRefPubMed Hirashima Y, Kobayashi H, Suzuki M, et al. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells. J Biol Chem. 2003;278:26793–802.CrossRefPubMed
21.
go back to reference Abratt RP, de Groot M, Willcox PA. Resection of a solitary brain metastasis in a patient with small cell lung cancer—long-term survival. Eur J Cancer. 1995;31A:419.CrossRefPubMed Abratt RP, de Groot M, Willcox PA. Resection of a solitary brain metastasis in a patient with small cell lung cancer—long-term survival. Eur J Cancer. 1995;31A:419.CrossRefPubMed
22.
go back to reference Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.CrossRefPubMed Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.CrossRefPubMed
23.
go back to reference Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer. 2004;45(Suppl 2):S253–7.CrossRefPubMed Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer. 2004;45(Suppl 2):S253–7.CrossRefPubMed
24.
25.
go back to reference He BP, Wang JJ, Zhang X, et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol Med. 2006;12:161–70.CrossRefPubMed He BP, Wang JJ, Zhang X, et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol Med. 2006;12:161–70.CrossRefPubMed
26.
go back to reference Vogelbaum MA, Mazzone P, Masaryk T. Low serum S100B levels in patients with newly diagnosed lung cancer correlate with an absence of brain metastases on MIR. Neuro-Oncology 2005;330–331. Vogelbaum MA, Mazzone P, Masaryk T. Low serum S100B levels in patients with newly diagnosed lung cancer correlate with an absence of brain metastases on MIR. Neuro-Oncology 2005;330–331.
27.
go back to reference Markowitz J, Mackerell AD Jr, Carrier F. Design of inhibitors for S100B. Curr Top Med Chem. 2005;5:1093–108.CrossRefPubMed Markowitz J, Mackerell AD Jr, Carrier F. Design of inhibitors for S100B. Curr Top Med Chem. 2005;5:1093–108.CrossRefPubMed
28.
go back to reference Shi AH, Zhu GY, Yu R. Whole brain irradiation for non-small-cell lung cancer with brain metastasis. Zhonghua Zhong Liu Za Zhi. 2007;29:545–8.PubMed Shi AH, Zhu GY, Yu R. Whole brain irradiation for non-small-cell lung cancer with brain metastasis. Zhonghua Zhong Liu Za Zhi. 2007;29:545–8.PubMed
29.
go back to reference Talmadge J, Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastases. Science. 1982;217:361–3.CrossRefPubMed Talmadge J, Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastases. Science. 1982;217:361–3.CrossRefPubMed
30.
go back to reference Marchetti D, Denkins Y, Reiland J, et al. Brain-metastatic melanoma: a neurotrophic perspective. Pathol Oncol Res. 2003;9:147–58.CrossRefPubMed Marchetti D, Denkins Y, Reiland J, et al. Brain-metastatic melanoma: a neurotrophic perspective. Pathol Oncol Res. 2003;9:147–58.CrossRefPubMed
31.
go back to reference Matsumoto S, Takahashi K, Iwakawa R, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer. 2006;119:1491–4.CrossRefPubMed Matsumoto S, Takahashi K, Iwakawa R, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer. 2006;119:1491–4.CrossRefPubMed
Metadata
Title
Biological characteristics of a specific brain metastatic cell line derived from human lung adenocarcinoma
Authors
Ling Hu
Junqing Zhang
Hongbin Zhu
Jie Min
Yingming Feng
Helong Zhang
Publication date
01-09-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9273-1

Other articles of this Issue 3/2010

Medical Oncology 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine